Trial Profile
Second of two planned phase II trials of betalutin for the treatment of non-Hodgkin's lymphoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2016
Price :
$35
*
At a glance
- Drugs Lutetium-177 lilotomab satetraxetan (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PARADIGME
- 24 Aug 2016 According to a Nordic Nanovector media release, optimized dose regimen of Lymrit 37-01 study will be used in PARADIGME study which is planned to start in 2H 2017.
- 15 Apr 2016 According to a Nordic Nanovector media release, the pivotal PARADIGME study expected to start in Q1 2017.
- 17 Nov 2015 According to Nordic Nanovector media release, based on the data from this and other trial the company plan for regulatory submission for Betalutin as a 3rd line treatment for patients with follicular lymphoma (FL) in first half of 2019.